65,437 trials
Adult Favorable Prognosis Hodgkin Lymphoma · Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 1; 0; 0 participants
Multiple Sclerosis · Neuropathic Pain
Primary: Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks) — -2.7; -1.4 units on a scale — p=0.005
Melanoma (Skin)
Primary: 5-year Overall Survival — 56; 56 Percent of population — p=0.49
Hypotrichosis
Primary: Percentage of Treatment Responders at Month 4 — 39.3; 10.9 Percentage of Subjects
Multiple Sclerosis
Primary: Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total) — -5.41; -7.51…
Rheumatoid Arthritis
Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months
Stomach Neoplasms
Primary: Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 15.4 percentage of participants
Dental Plaque
Primary: Residual Protein Concentration — 33.5; 28; 20.4; 20.2 ug/mL
Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 20 participants
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Endometritis
Primary: Endometritis Incidence — 0; 0 participants
Ischemic Stroke
Primary: Symptomatic and Radiographic Intracerebral Hemorrhage — 6.2 percentage of patients
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Smoking
Primary: Continuous Abstinence at 12 Weeks Post Target Quit Date — 3; 2 participants
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period — 4.9; 4.1 units on a scale